参考文献/References:
[1]王莹,王菊英.HE4、CA125、CA153在早期上皮性卵巢癌中的诊断价值[J].宁夏医学杂志,2021,43(9):832-834.[2]Luvero D,Milani A,Ledermann JA.Treatment options in recurrent ovarian cancer: latest evidence and clinical potential[J].Therapeutic advances in medical oncology,2014,6(5):229-239.[3]Chen DS,Mellman I.Oncology meets immunology:the cancer-immunity cycle[J].Immunity,2013,39(1):1-10.[4]Pinto MP,Balmaceda C,Bravo ML,et al.Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer [J].Gynecologic Oncology,2018,151(1):10-17.[5]李贺群,徐晖,严波,等.晚期卵巢癌患者卵巢癌组织中免疫细胞表达水平与新辅助化疗敏感性的关系[J].癌症进展,2019,17(3):344-347,365.[6]熊璐,苑雪萍,徐冲,等.基于生物信息学分析卵巢癌免疫细胞浸润程度及其与预后的关系[J].国际检验医学杂志,2021,42(17):2141-2145.[7]Santoiemma PP,Powell DJ.Tumor infiltrating lymphocytes in ovarian cancer[J].Cancer biology & Therapy,2015,16(6):807-820.[8]Yildirim N,Akman L,Acar K,et al.Do tumor-infiltrating lymphocytes really indicate favorable prognosis in epithelial ovarian cancer?[J].European Journal of Obstetrics,Gynecology,and Reproductive Biology,2017,215:55-61.[9]Santoiemma PP,Reyes C,Wang LP,et al.Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer[J].Gynecologic oncology,2016,143(1):120-127.[10]翟振伟.卵巢癌组织中肿瘤浸润淋巴细胞分布特征与患者预后的关系[J].医学信息,2010,23(5):1132-1134.[11]吴小丽,张婷,王昕婧,等.上皮性卵巢癌患者肿瘤局部微环境中Treg/Th17比例平衡的研究[J].现代妇产科进展,2014,23(10):769-773.[12]胡喜珍,丁杰,梁常艳.肿瘤浸润淋巴细胞在浆液性卵巢癌的临床病理分析[J].实用妇产科杂志,2017,33(10):764-768.[13]James FR,Jiminez-Linan M,Alsop J,et al.Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer[J].BMC cancer,2017,17(1):657.[14]张娟娟,张春莲,张志军,等.基于CD133及上皮-间质转化相关因子的列线图模型对上皮性卵巢癌预后的预测价值[J].安徽医药,2019,23(8):1600-1603.[15]朱亚飞,张文书,叶萍,等.HE4和CA125在高、低级别浆液性卵巢癌中表达差异的对照研究[J].赣南医学院学报,2018,38(1):11-15.[16]管东东,张磊磊,王云芳,等.卵巢癌组织中STAT3和免疫效应细胞的表达及其相关性分析[J].现代妇产科进展,2011,20(2):88-91.[17]Leffers N,Gooden MJ,De Jong RA,et al.Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer[J].Cancer Immunology, Immunotherapy,2009,58(3):449-459.[18]Stanske M,Wienert S,Castillo-Tong DC,et al.Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer[J].Neoplasia (New York, NY),2018,20(3):280-288.[19]Hollis RL,Carmichael J,Meynert AM,et al.Clinical and molecular characterization of ovarian carcinoma displaying isolated lymph node relapse[J].American Journal of Obstetrics and Gynecology,2019,221(3):245.e1-e15.[20]Khairallah AS,Genestie C,Auguste A,et al.Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications [J].International journal of cancer,2018,143(1):8-15.[21]李荣,周怀君,吴婵.新辅助化疗联合肿瘤细胞减灭术对晚期卵巢癌患者血清CA125及免疫功能的影响 [J].贵州医药,2018,42(12):1462-1463.[22]杨群,周春香,韩宸,等.新辅助同步放化疗对直肠癌微环境浸润免疫细胞的影响[J].南方医科大学学报,2021,41(8):1270-1276.[23]Mesnage SJL,Auguste A,Genestie C,et al.Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC) [J]. Annals of Oncology,2017,28(3):651-657.[24]Lo CS,Sanii S,Kroeger DR,et al.Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy [J].Clinical cancer Research,2017,23(4):925-934.[25]B?觟hm S,Montfort A,Pearce OM,et al.Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma[J].Clinical Cancer Research,2016,22(12):3025-3036.[26]高庆蕾.卵巢癌与基因检测的规范化[J].中国实用妇科与产科杂志,2021,37(6):605-609.[27]Xiao X,Dong D,He W,et al.Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer[J].Gynecologic Oncology,2018,149(1):146-154.[28]Aysal A,Karnezis A,Medhi I,et al.Ovarian endometrioid adenocarcinoma: incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability[J].The American Journal of Surgical Pathology,2012,36(2):163-172.[29]Konstantinopoulos PA,Ceccaldi R,Shapiro GI,et al.Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer[J].Cancer Discovery,2015,5(11):1137-1154.[30]Strickland KC,Howitt BE,Shukla SA,et al.Association and prognostic significance of BRCA1/2-mutation status with neoantigen load,number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer[J].Oncotarget,2016,7(12):13587-13598.